US5795870A
(en)
*
|
1991-12-13 |
1998-08-18 |
Trustees Of Princeton University |
Compositions and methods for cell transformation
|
US5670347A
(en)
|
1994-05-11 |
1997-09-23 |
Amba Biosciences Llc |
Peptide-mediated gene transfer
|
US5837533A
(en)
*
|
1994-09-28 |
1998-11-17 |
American Home Products Corporation |
Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
|
US6383814B1
(en)
|
1994-12-09 |
2002-05-07 |
Genzyme Corporation |
Cationic amphiphiles for intracellular delivery of therapeutic molecules
|
US6331524B1
(en)
|
1994-12-09 |
2001-12-18 |
Genzyme Corporation |
Organ-specific targeting of cationic amphiphile / DNA complexes for gene therapy
|
US5948767A
(en)
*
|
1994-12-09 |
1999-09-07 |
Genzyme Corporation |
Cationic amphiphile/DNA complexes
|
US5719131A
(en)
*
|
1994-12-09 |
1998-02-17 |
Genzyme Corporation |
Cationic amphiphiles containing dialkylamine lipophilic groups for intracellular delivery of therapeutic molecules
|
US6071890A
(en)
*
|
1994-12-09 |
2000-06-06 |
Genzyme Corporation |
Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
|
US5747471A
(en)
*
|
1994-12-09 |
1998-05-05 |
Genzyme Corporation |
Cationic amphiphiles containing steroid lipophilic groups for intracellular delivery of therapeutic molecules
|
US5840710A
(en)
*
|
1994-12-09 |
1998-11-24 |
Genzyme Corporation |
Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules
|
US5767099A
(en)
*
|
1994-12-09 |
1998-06-16 |
Genzyme Corporation |
Cationic amphiphiles containing amino acid or dervatized amino acid groups for intracellular delivery of therapeutic molecules
|
US5650096A
(en)
*
|
1994-12-09 |
1997-07-22 |
Genzyme Corporation |
Cationic amphiphiles for intracellular delivery of therapeutic molecules
|
US5910487A
(en)
*
|
1994-12-09 |
1999-06-08 |
Genzyme Corporation |
Cationic amphiphiles and plasmids for intracellular delivery of therapeutic molecules
|
US5795587A
(en)
|
1995-01-23 |
1998-08-18 |
University Of Pittsburgh |
Stable lipid-comprising drug delivery complexes and methods for their production
|
US6008202A
(en)
|
1995-01-23 |
1999-12-28 |
University Of Pittsburgh |
Stable lipid-comprising drug delivery complexes and methods for their production
|
US20030069173A1
(en)
*
|
1998-03-16 |
2003-04-10 |
Life Technologies, Inc. |
Peptide-enhanced transfections
|
JP4338106B2
(ja)
*
|
1995-06-07 |
2009-10-07 |
ライフ テクノロジーズ コーポレーション |
ペプチド増強カチオン脂質トランスフェクション
|
US6051429A
(en)
|
1995-06-07 |
2000-04-18 |
Life Technologies, Inc. |
Peptide-enhanced cationic lipid transfections
|
FR2736642B1
(fr)
*
|
1995-07-10 |
1997-09-12 |
Pasteur Institut |
Immunovecteurs, notamment anticorps et fragments d'anticorps utilisables pour le transport intracellulaire et intranucleaire de principes biologiquement actifs notamment d'haptenes, de proteines et d'acides nucleiques
|
FR2741066B1
(fr)
*
|
1995-11-14 |
1997-12-12 |
Rhone Poulenc Rorer Sa |
Nouveaux agents de transfection et leurs applications pharmaceutiques
|
US7002027B1
(en)
*
|
1996-01-08 |
2006-02-21 |
Canji, Inc. |
Compositions and methods for therapeutic use
|
US6392069B2
(en)
|
1996-01-08 |
2002-05-21 |
Canji, Inc. |
Compositions for enhancing delivery of nucleic acids to cells
|
FR2744453B1
(fr)
*
|
1996-02-05 |
1998-07-10 |
Transgene Sa |
Composes lipopolyamines, compositions pharmaceutiques en comprenant, vecteurs de transfert d'acide nucleique et procede de preparation
|
DE69736385T2
(de)
*
|
1996-02-09 |
2007-08-23 |
Pi-Wan Cheng |
Kationisches lipid und rezeptorligand erleichterte gabe von biologisch aktiven molekuelen
|
JP4340330B2
(ja)
*
|
1996-05-24 |
2009-10-07 |
アイシー‐ヴェック・リミテッド |
トランスフェクション剤としてのポリカチオン性ステロール誘導体
|
US5935936A
(en)
*
|
1996-06-03 |
1999-08-10 |
Genzyme Corporation |
Compositions comprising cationic amphiphiles and co-lipids for intracellular delivery of therapeutic molecules
|
AU3514197A
(en)
|
1996-07-03 |
1998-01-21 |
Genetics Institute Inc. |
Protease fmh-1, an ice/ced-like protease
|
CN1181422A
(zh)
*
|
1996-10-31 |
1998-05-13 |
上海市肿瘤研究所 |
与生长因子受体结合的多肽所构建的基因转移载体
|
GB9623051D0
(en)
*
|
1996-11-06 |
1997-01-08 |
Schacht Etienne H |
Delivery of DNA to target cells in biological systems
|
US20060002949A1
(en)
|
1996-11-14 |
2006-01-05 |
Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. |
Transcutaneous immunization without heterologous adjuvant
|
US6797276B1
(en)
|
1996-11-14 |
2004-09-28 |
The United States Of America As Represented By The Secretary Of The Army |
Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
|
US5925628A
(en)
*
|
1997-03-31 |
1999-07-20 |
Genzyme Corporation |
Cationic amphiphiles for intracellular delivery of therapeutic molecules
|
US5912239A
(en)
*
|
1997-04-04 |
1999-06-15 |
Genzyme Corporation |
Imidazole-containing cationic amphiphiles for intracellular delivery of therapeutic molecules
|
US5948925A
(en)
*
|
1997-05-06 |
1999-09-07 |
Genzyme Corporation |
Cationic amphiphiles containing linkers derived from neutral or positively charged amino acids
|
US5952516A
(en)
*
|
1997-05-08 |
1999-09-14 |
Genzyme Corporation |
Cationic amphiphiles containing multiplesteroid lipophilic groups
|
US5942634A
(en)
*
|
1997-05-09 |
1999-08-24 |
Genzyme Corporation |
Cationic amphiphiles for cell transfections
|
TW586934B
(en)
*
|
1997-05-19 |
2004-05-11 |
Sumitomo Pharma |
Immunopotentiating composition
|
US6818627B1
(en)
|
1997-08-14 |
2004-11-16 |
The Trustees Of The University Of Pennsylvania |
Functional fragments of HIV-1 Vpr protein and methods of using the same
|
EP2218731A1
(en)
|
1997-11-28 |
2010-08-18 |
Merck Serono Biodevelopment |
Chlamydia trachomatis genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection
|
FR2774394B1
(fr)
*
|
1998-01-30 |
2002-04-26 |
Rhone Poulenc Rorer Sa |
Composes transfectants sensibles aux conditions reductrices, compositions pharmaceutiques les contenant, et leurs applications
|
WO1999038821A2
(fr)
|
1998-01-30 |
1999-08-05 |
Aventis Pharma S.A. |
Composes transfectants sensibles aux conditions reductrices, compositions pharmaceutiques les contenant, et leurs applications
|
CA2792479A1
(en)
|
1998-02-27 |
1999-09-02 |
The Trustees Of The University Of Pennsylvania |
Vaccines, immunotherapeutics and methods for using the same
|
US6583301B1
(en)
*
|
1998-04-08 |
2003-06-24 |
Celltech R & D Limited |
Lipids
|
EP1254961A1
(en)
*
|
1998-05-06 |
2002-11-06 |
Transgene S.A. |
Improvments in gene therapy using compositions comprising a polynucleotide and interleukin-10
|
EP0963758A3
(en)
*
|
1998-05-07 |
2000-03-22 |
Universiteit Gent |
Synthetic polyaminoacid complexes for delivery of nucleic acids to target cells
|
US6596699B2
(en)
|
1998-09-22 |
2003-07-22 |
Biosurface Engineering Technologies, Inc. |
Nucleic acid coating compositions and methods
|
ES2296419T3
(es)
|
1998-11-12 |
2008-04-16 |
Invitrogen Corporation |
Reactivos de transfeccion.
|
US7148324B1
(en)
|
1998-12-14 |
2006-12-12 |
Dendreon Corporation |
Compositions and methods for enhancement of major histocompatibility complex class I restricted antigen presentation
|
AU775767B2
(en)
*
|
1998-12-14 |
2004-08-12 |
Dendreon Corporation |
Compositions and methods for enhancement of major histocompatibility complex class I restricted antigen presentation
|
WO2000038733A1
(en)
|
1998-12-24 |
2000-07-06 |
Ucb S.A. |
Peptidic product, process and composition
|
EP1147204A1
(en)
*
|
1999-01-28 |
2001-10-24 |
Medical College Of Georgia Research Institute, Inc. |
Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
|
IL145778A0
(en)
|
1999-04-21 |
2002-07-25 |
American Home Prod |
Methods and compositions for inhibiting the function of polynucleotide sequences
|
KR20080052690A
(ko)
*
|
1999-04-30 |
2008-06-11 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
돌연변이체 인간 cd80, 이를 포함하는 조성물, 및 이를제조하고 이용하는 방법
|
AUPQ014799A0
(en)
*
|
1999-05-04 |
1999-05-27 |
Access Pharmaceuticals Australia Pty Limited |
Amplification of folate-mediated targeting to tumor cells using polymers
|
AUPQ014699A0
(en)
*
|
1999-05-04 |
1999-05-27 |
Access Pharmaceuticals Australia Pty Limited |
Amplification of folate-mediated targeting to tumor cells using nanoparticles
|
US6565528B1
(en)
|
1999-05-07 |
2003-05-20 |
Scimed Life Systems, Inc. |
Apparatus and method for delivering therapeutic and diagnostic agents
|
US7147633B2
(en)
|
1999-06-02 |
2006-12-12 |
Boston Scientific Scimed, Inc. |
Method and apparatus for treatment of atrial fibrillation
|
EP1187652B1
(en)
|
1999-06-02 |
2006-10-11 |
Boston Scientific Limited |
Devices for delivering a drug
|
GB9914045D0
(en)
*
|
1999-06-16 |
1999-08-18 |
Smithkline Beecham Plc |
Novel compounds
|
GB9914085D0
(en)
*
|
1999-06-16 |
1999-08-18 |
Smithkline Beecham Plc |
New use
|
GB9918670D0
(en)
|
1999-08-06 |
1999-10-13 |
Celltech Therapeutics Ltd |
Biological product
|
US6528258B1
(en)
|
1999-09-03 |
2003-03-04 |
Lifebeam Technologies, Inc. |
Nucleic acid sequencing using an optically labeled pore
|
US6312474B1
(en)
*
|
1999-09-15 |
2001-11-06 |
Bio-Vascular, Inc. |
Resorbable implant materials
|
US6933108B2
(en)
|
1999-12-09 |
2005-08-23 |
The Regents Of The University Of California |
Methods and compositions for use in the treatment of filovirus mediated disease conditions
|
AU2256801A
(en)
*
|
1999-12-09 |
2001-06-18 |
Regents Of The University Of California, The |
Methods and compositions for use in the treatment of filovirus mediated disease conditions
|
CN1414864A
(zh)
*
|
1999-12-22 |
2003-04-30 |
宾夕法尼亚大学理事会 |
粘粒dna构建体以及制备和使用该构建体的方法
|
JP2003519199A
(ja)
*
|
1999-12-30 |
2003-06-17 |
ノバルティス アクチエンゲゼルシャフト |
遺伝子治療のための新規なコロイド合成ベクター
|
US7355019B2
(en)
*
|
2000-06-06 |
2008-04-08 |
Sibtech, Inc. |
Cysteine-containing peptide tag for site-specific conjugation of proteins
|
WO2002006303A2
(en)
*
|
2000-07-14 |
2002-01-24 |
The Trustees Of The University Of Pennsylvania |
Dna vaccines encoding hiv accessory proteins
|
WO2002010410A1
(en)
*
|
2000-07-27 |
2002-02-07 |
The Trustees Of The University Of Pennsylvania |
Compositions for and methods of using herpes simplex virus glycoprotein d to suppress immune responses
|
US6733994B2
(en)
*
|
2000-10-04 |
2004-05-11 |
The Trustees Of The University Of Pennsylvania |
Highly expressible genes
|
EP1330516B1
(en)
*
|
2000-11-03 |
2007-01-17 |
The Regents Of The University Of Michigan |
Surface transfection and expression procedure
|
US6897067B2
(en)
*
|
2000-11-03 |
2005-05-24 |
Regents Of The University Of Michigan |
Surface transfection and expression procedure
|
US6902933B2
(en)
*
|
2000-11-03 |
2005-06-07 |
Regents Of The University Of Michigan |
Surface transfection and expression procedure
|
US20020188023A1
(en)
*
|
2000-12-12 |
2002-12-12 |
Michael Jorgensen |
Compound
|
BR0208874A
(pt)
*
|
2001-04-13 |
2004-06-22 |
Wyeth Corp |
Proteìnas superficiais de streptococcus pyogenes
|
US20070128229A1
(en)
*
|
2002-04-12 |
2007-06-07 |
Wyeth |
Surface proteins of Streptococcus pyogenes
|
EP2261241A1
(en)
|
2001-04-16 |
2010-12-15 |
Wyeth Holdings Corporation |
Streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof
|
GB0120022D0
(en)
|
2001-08-16 |
2001-10-10 |
Photobiotics Ltd |
Conjugate
|
MX339524B
(es)
|
2001-10-11 |
2016-05-30 |
Wyeth Corp |
Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
|
WO2003040399A2
(en)
*
|
2001-11-02 |
2003-05-15 |
Intradigm Corporation |
Therapeutic methods for nucleic acid delivery vehicles
|
US20030170216A1
(en)
|
2001-12-20 |
2003-09-11 |
Schering-Plough Corporation |
SYN3 compositions and methods
|
US7026166B2
(en)
*
|
2002-01-22 |
2006-04-11 |
Chiron Corporation |
Fluorogenic dyes
|
AU2003217355B2
(en)
*
|
2002-02-07 |
2009-04-23 |
University Of Utah Research Foundation |
Method for creating and using a treatment protocol
|
US20050222064A1
(en)
*
|
2002-02-20 |
2005-10-06 |
Sirna Therapeutics, Inc. |
Polycationic compositions for cellular delivery of polynucleotides
|
MXPA04008890A
(es)
*
|
2002-03-15 |
2005-10-18 |
Wyeth Corp |
Mutantes de la proteina p4 de haemophilus influenzae no tipicable con actividad enzimatica reducida.
|
US20040180438A1
(en)
*
|
2002-04-26 |
2004-09-16 |
Pachuk Catherine J. |
Methods and compositions for silencing genes without inducing toxicity
|
CA2385110A1
(en)
*
|
2002-05-06 |
2003-11-06 |
University Of British Columbia |
Co-expression system for large functional proteins
|
US20060110790A1
(en)
*
|
2002-05-06 |
2006-05-25 |
Robert Molday |
Expression system for large functional proteins
|
CA2487274A1
(en)
*
|
2002-05-06 |
2003-11-13 |
Nucleonics Inc. |
Spermine chemically linked to lipids and cell-specific targeting molecules as a transfection agent
|
US20050239728A1
(en)
*
|
2002-07-31 |
2005-10-27 |
Pachuk Catherine J |
Double stranded rna structures and constructs, and methods for generating and using the same
|
US7785608B2
(en)
|
2002-08-30 |
2010-08-31 |
Wyeth Holdings Corporation |
Immunogenic compositions for the prevention and treatment of meningococcal disease
|
US7144588B2
(en)
|
2003-01-17 |
2006-12-05 |
Synovis Life Technologies, Inc. |
Method of preventing surgical adhesions
|
US7704756B2
(en)
*
|
2003-01-21 |
2010-04-27 |
Novartis Vaccines And Diagnostics, Inc. |
Fluorogenic dyes
|
SI1592457T1
(sl)
*
|
2003-01-27 |
2012-12-31 |
Endocyte, Inc. |
Konjugat folat-vinblastin kot zdravilo
|
NZ543970A
(en)
|
2003-06-04 |
2008-09-26 |
Canji Inc |
Methods and compositions for interferon therapy
|
KR20060012661A
(ko)
*
|
2003-06-04 |
2006-02-08 |
캔지, 인크. |
인터페론 요법을 위한 방법 및 조성물
|
SG173218A1
(en)
|
2003-06-12 |
2011-08-29 |
Alnylam Pharmaceuticals Inc |
Conserved hbv and hcv sequences useful for gene silencing
|
CA2529752A1
(en)
*
|
2003-06-20 |
2005-09-15 |
The Regents Of The University Of California |
Polypeptide transduction and fusogenic peptides
|
JP2007503205A
(ja)
*
|
2003-08-22 |
2007-02-22 |
ニュークレオニクス・インコーポレイテッド |
多コンパートメント真核生物発現系
|
US20090208478A1
(en)
*
|
2003-10-24 |
2009-08-20 |
Gencia Corporation |
Transducible polypeptides for modifying metabolism
|
US8062891B2
(en)
|
2003-10-24 |
2011-11-22 |
Gencia Corporation |
Nonviral vectors for delivering polynucleotides to plants
|
CA2543257C
(en)
|
2003-10-24 |
2013-12-31 |
Gencia Corporation |
Methods and compositions for delivering polynucleotides
|
US8133733B2
(en)
|
2003-10-24 |
2012-03-13 |
Gencia Corporation |
Nonviral vectors for delivering polynucleotides to target tissues
|
US20090123468A1
(en)
|
2003-10-24 |
2009-05-14 |
Gencia Corporation |
Transducible polypeptides for modifying metabolism
|
US8507277B2
(en)
|
2003-10-24 |
2013-08-13 |
Gencia Corporation |
Nonviral vectors for delivering polynucleotides
|
US7740861B2
(en)
|
2004-06-16 |
2010-06-22 |
University Of Massachusetts |
Drug delivery product and methods
|
TW200613554A
(en)
|
2004-06-17 |
2006-05-01 |
Wyeth Corp |
Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
|
DE602005024015D1
(de)
|
2004-08-23 |
2010-11-18 |
Alnylam Pharmaceuticals Inc |
Expressionskonstrukte mit mehreren rna-polymerase-iii-promotoren
|
WO2006032039A2
(en)
*
|
2004-09-17 |
2006-03-23 |
University Of Massachusetts |
Compositions and their uses for lysosomal enzyme deficiencies
|
EP1797185B1
(en)
|
2004-09-24 |
2011-04-13 |
Alnylam Pharmaceuticals, Inc. |
Targeting opposite strand replication intermediates of single-stranded viruses by rnai
|
WO2007001423A2
(en)
|
2004-10-21 |
2007-01-04 |
Wyeth |
Immunogenic compositions of staphylococcus epidermidis polypeptide and polynucleotide antigens
|
EP2316942B1
(en)
|
2004-12-22 |
2021-04-21 |
Alnylam Pharmaceuticals, Inc. |
Conserved hbv and hcv sequences useful for gene silencing
|
US20090182019A1
(en)
*
|
2005-04-18 |
2009-07-16 |
The Johns Hopkins University |
Histone deacetylase inhibitors
|
US20070087045A1
(en)
*
|
2005-10-14 |
2007-04-19 |
Industrial Technology Research Institute |
Lipid carrier and method of preparing the same
|
ATE526991T1
(de)
*
|
2005-10-24 |
2011-10-15 |
Univ Massachusetts |
Zusammensetzungen und ihre verwendungen für die gentherapeutische behandlung von knochenerkrankungen
|
WO2007082105A2
(en)
|
2006-01-16 |
2007-07-19 |
Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chlamydia vaccine
|
WO2007118245A2
(en)
|
2006-04-07 |
2007-10-18 |
The Board Of Regents Of The University Of Texas System |
Methods and compositions related to adenoassociated virus-phage particles
|
WO2008118212A2
(en)
*
|
2006-11-08 |
2008-10-02 |
Veritas, Llc |
In vivo delivery of double stranded rna to a target cell
|
EP1935434A1
(en)
*
|
2006-12-19 |
2008-06-25 |
Novosom AG |
Construction and use of transfection enhancer elements
|
AR064642A1
(es)
|
2006-12-22 |
2009-04-15 |
Wyeth Corp |
Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
|
US20100297023A1
(en)
*
|
2006-12-22 |
2010-11-25 |
Imuthes Limited University Of The Witwatersrand |
Lipid
|
EP2111218B1
(en)
*
|
2007-01-24 |
2014-07-02 |
Syddansk Universitet |
Dna controlled assembly of lipid membranes
|
US10265407B2
(en)
|
2007-02-15 |
2019-04-23 |
Yale University |
Modular nanodevices for smart adaptable vaccines
|
WO2008115641A2
(en)
*
|
2007-02-15 |
2008-09-25 |
Yale University |
Modular nanoparticles for adaptable vaccines
|
WO2008109347A2
(en)
*
|
2007-03-02 |
2008-09-12 |
Yale University |
Methods for ex vivo administration of drugs to grafts using polymeric nanoparticles
|
DK2494993T3
(en)
*
|
2007-05-04 |
2018-11-12 |
Marina Biotech Inc |
Amino acid lipids and uses thereof
|
WO2008138072A1
(en)
|
2007-05-16 |
2008-11-20 |
Mat Malta Advanced Technologies Limited |
Treatment and prevention of influenza
|
US7973019B1
(en)
|
2007-10-03 |
2011-07-05 |
Alcon Research, Ltd. |
Transferrin/transferrin receptor-mediated siRNA delivery
|
JP2011517279A
(ja)
*
|
2007-10-29 |
2011-06-02 |
ユニバーシティ オブ マサチューセッツ |
核酸(siRNA)送達用の酵母細胞壁粒子(YCWP)多層状ナノ粒子
|
US7928189B2
(en)
*
|
2008-05-05 |
2011-04-19 |
Ottawa Health Research Institute |
PCSK9 polypeptide fragment
|
RU2010151562A
(ru)
|
2008-06-20 |
2012-07-27 |
ВАЙЕТ ЭлЭлСи (US) |
Композиции и способы применения orf1358 из бета-гемолитических стрептококковых штаммов
|
US8815818B2
(en)
|
2008-07-18 |
2014-08-26 |
Rxi Pharmaceuticals Corporation |
Phagocytic cell delivery of RNAI
|
US20110111044A1
(en)
*
|
2008-07-31 |
2011-05-12 |
Enzon Pharmaceuticals, Inc. |
Nanoparticle compositions for nucleic acids delivery system
|
CN108165548B
(zh)
|
2008-09-22 |
2022-10-14 |
菲奥医药公司 |
减小大小的自递送RNAi化合物
|
KR20110081282A
(ko)
*
|
2008-11-05 |
2011-07-13 |
와이어쓰 엘엘씨 |
베타―용혈성 연쇄구균 (bhs) 질환의 예방을 위한 다성분 면역원성 조성물
|
WO2010078536A1
(en)
|
2009-01-05 |
2010-07-08 |
Rxi Pharmaceuticals Corporation |
Inhibition of pcsk9 through rnai
|
CN102333863A
(zh)
|
2009-01-13 |
2012-01-25 |
干细胞生物科技公司 |
非胚胎干细胞及其用途
|
JP5802195B2
(ja)
|
2009-04-27 |
2015-10-28 |
オタワ ホスピタル リサーチ インスティチュート |
幹細胞を調節するための組成物および方法ならびにその使用
|
JP5883381B2
(ja)
|
2009-05-05 |
2016-03-15 |
ミラゲン セラピューティクス,インコーポレイテッド |
親油性ポリヌクレオチド接合体
|
MX2011013176A
(es)
|
2009-06-08 |
2012-04-30 |
Miragen Therapeutics |
Motivos de modificación química para inhibidores y miméticos del miarn.
|
WO2011084721A2
(en)
*
|
2009-12-21 |
2011-07-14 |
Agave Pharma Inc |
Cationic molecule and method of use
|
EA024534B1
(ru)
*
|
2010-02-24 |
2016-09-30 |
Эрроухэд Рисерч Корпорейшн |
КОНЪЮГИРОВАННАЯ СИСТЕМА ДОСТАВКИ И КОМПОЗИЦИЯ ДЛЯ НАПРАВЛЕННОЙ ДОСТАВКИ МАЛЫХ ИНТЕРФЕРИРУЮЩИХ РНК (миРНК) И СПОСОБ ПОЛУЧЕНИЯ КОМПОЗИЦИИ
|
JP6022455B2
(ja)
|
2010-08-04 |
2016-11-09 |
ステムバイオス テクノロジーズ,インコーポレイテッド |
体性幹細胞
|
CA2808975C
(en)
|
2010-08-23 |
2018-10-30 |
Wyeth Llc |
Stable formulations of neisseria meningitidis rlp2086 antigens
|
JP5976652B2
(ja)
|
2010-09-10 |
2016-08-24 |
ワイス・エルエルシー |
髄膜炎菌orf2086抗原の非脂質化変異体
|
JP5995855B2
(ja)
|
2010-11-05 |
2016-09-21 |
ミラゲン セラピューティクス,インコーポレイテッド |
塩基修飾オリゴヌクレオチド
|
CN103415615B
(zh)
|
2010-11-24 |
2015-11-25 |
高红 |
扩增造血干细胞
|
SG190355A1
(en)
|
2010-12-15 |
2013-07-31 |
Miragen Therapeutics |
Microrna inhibitors comprising locked nucleotides
|
CA2832899A1
(en)
|
2011-04-12 |
2012-10-18 |
Beth Israel Deaconess Medical Center, Inc. |
Micro-rna inhibitors and their uses in disease
|
WO2013037065A1
(en)
|
2011-09-13 |
2013-03-21 |
Ottawa Hospital Research Institute |
Microrna inhibitors
|
AU2012321103B2
(en)
|
2011-09-16 |
2016-05-12 |
Ottawa Hospital Research Institute |
Wnt7a compositions and methods of using the same
|
JP2014527818A
(ja)
|
2011-09-16 |
2014-10-23 |
フェイト セラピューティクス,インコーポレイテッド |
Wnt組成物およびそのような組成物の治療的使用
|
TWI571513B
(zh)
|
2011-09-28 |
2017-02-21 |
幹細胞生物科技股份有限公司 |
體幹細胞及其製備方法
|
JP6053688B2
(ja)
|
2011-10-07 |
2016-12-27 |
国立大学法人三重大学 |
キメラ抗原受容体
|
US20140335117A1
(en)
*
|
2011-10-07 |
2014-11-13 |
Skau Aps |
Identification and Attenuation of the Immunosuppressive Domains in Fusion Proteins of Enveloped RNA Viruses
|
SA115360586B1
(ar)
|
2012-03-09 |
2017-04-12 |
فايزر انك |
تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
|
CN104334187B
(zh)
|
2012-03-09 |
2017-04-05 |
辉瑞公司 |
脑膜炎双球菌组合物及其方法
|
EP2841098A4
(en)
|
2012-04-23 |
2016-03-02 |
Allertein Therapeutics Llc |
NANOPARTICLES FOR THE TREATMENT OF ALLERGIES
|
EP2864482A4
(en)
|
2012-06-21 |
2016-02-10 |
Miragen Therapeutics Inc |
OLIGONUCLEOTIDE INHIBITORS COMPRISING A BLOCKED NUCLEIC ACID PATTERN
|
CN105408347A
(zh)
*
|
2013-02-15 |
2016-03-16 |
纽约血库公司 |
寡聚流感免疫原性组合物
|
JP6446377B2
(ja)
|
2013-03-08 |
2018-12-26 |
ファイザー・インク |
免疫原性融合ポリペプチド
|
CA2902623A1
(en)
|
2013-03-15 |
2014-09-25 |
MiRagen Therapeutics, Inc. |
Locked nucleic acid inhibitor of mir-145 and uses thereof
|
AU2014233115B2
(en)
|
2013-03-15 |
2019-08-01 |
MiRagen Therapeutics, Inc. |
Bridged bicyclic nucleosides
|
CA2907915C
(en)
|
2013-04-03 |
2023-03-07 |
Allertein Therapeutics, Llc |
Immunomodulatory nanoparticle compositions comprising a plurality of nanoparticles comprising biodegradable or biocompatible polymers and hydrophilic and hydrophobic cellular components
|
US9428748B2
(en)
|
2013-06-17 |
2016-08-30 |
Hong Gao |
Method of expanding hematopoietic stem cells
|
WO2015033251A2
(en)
|
2013-09-08 |
2015-03-12 |
Pfizer Inc. |
Neisseria meningitidis compositions and methods thereof
|
EP3068783B1
(en)
|
2013-11-15 |
2020-09-23 |
The Board of Trustees of the Leland Stanford Junior University |
Agonists of hypocretin receptor 2 for use for treating heart failure
|
US10772974B2
(en)
|
2013-11-18 |
2020-09-15 |
Beth Israel Deaconess Medical Center, Inc. |
Compositions and methods for cardiac regeneration
|
EP3169310A1
(en)
|
2014-07-15 |
2017-05-24 |
Life Technologies Corporation |
Compositions with lipid aggregates and methods for efficient delivery of molecules to cells
|
AR101449A1
(es)
|
2014-08-04 |
2016-12-21 |
Miragen Therapeutics Inc |
Inhibidores de myh7b y usos de los mismos
|
AU2015315298B2
(en)
|
2014-09-08 |
2020-05-14 |
MiRagen Therapeutics, Inc. |
miR-29 mimics and uses thereof
|
EA201791644A1
(ru)
|
2015-01-20 |
2018-01-31 |
Мираджен Терапьютикс, Инк. |
Ингибиторы mir-92 и их применение
|
CN107249626A
(zh)
|
2015-02-19 |
2017-10-13 |
辉瑞大药厂 |
脑膜炎奈瑟球菌组合物及其方法
|
US10624964B2
(en)
|
2015-05-01 |
2020-04-21 |
The Trustees Of The University Of Pennsylvania |
Methods and compositions for stimulating immune response using potent immunostimulatory RNA motifs
|
NZ737542A
(en)
|
2015-06-05 |
2019-09-27 |
Miragen Therapeutics Inc |
Mir-155 inhibitors for treating cutaneous t cell lymphoma (ctcl)
|
CA2994969A1
(en)
|
2015-08-06 |
2017-02-09 |
Dana-Farber Cancer Institute, Inc. |
Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses
|
CA3005434A1
(en)
|
2015-11-16 |
2017-05-26 |
Ohio State Innovation Foundation |
Methods and compositions for treating disorders and diseases using survival motor neuron (smn) protein
|
US11052111B2
(en)
|
2015-12-08 |
2021-07-06 |
Chimera Bioengineering, Inc. |
Smart CAR devices and DE CAR polypeptides for treating disease and methods for enhancing immune responses
|
WO2017157950A1
(en)
|
2016-03-15 |
2017-09-21 |
Johann Wolfgang Goethe-Universität |
Light inducible antisense oligonucleotides for in vivo application
|
UY37376A
(es)
|
2016-08-26 |
2018-03-23 |
Amgen Inc |
Construcciones de arni para inhibir expresión de asgr1 y métodos para su uso
|
JP7045378B2
(ja)
|
2016-09-01 |
2022-03-31 |
キメラ・バイオエンジニアリング,インコーポレーテッド |
Gold最適化CAR T細胞
|
ES2659845B1
(es)
|
2016-09-19 |
2019-01-04 |
Univ Valencia |
Modulación de microRNAs contra la distrofia miotónica tipo 1 y antagonistas de microRNAs para ello
|
KR102567845B1
(ko)
|
2017-01-31 |
2023-08-17 |
화이자 인코포레이티드 |
네이세리아 메닌기티디스 조성물 및 그의 방법
|
EP4119552A1
(en)
|
2017-02-08 |
2023-01-18 |
Dana-Farber Cancer Institute, Inc. |
Regulating chimeric antigen receptors
|
AR113490A1
(es)
|
2017-12-12 |
2020-05-06 |
Amgen Inc |
CONSTRUCCIONES DE ARNi PARA INHIBIR LA EXPRESIÓN DE PNPLA3 Y MÉTODOS DE USO DE LAS MISMAS
|
CN111918968B
(zh)
|
2018-03-14 |
2023-11-24 |
贝斯以色列女执事医疗中心 |
Micro-RNA 22的抑制剂
|
US20240216509A1
(en)
|
2018-05-07 |
2024-07-04 |
Children's Hospital Medical Center |
Chimeric polypeptides, nucleic acid molecules, cells, and related methods
|
BR112021011061A2
(pt)
|
2018-12-10 |
2021-08-31 |
Amgen Inc. |
Construtos de rnai para inibir a expressão de pnpla3
|
WO2020123410A1
(en)
|
2018-12-10 |
2020-06-18 |
Amgen Inc. |
CHEMICALLY-MODIFIED RNAi CONSTRUCTS AND USES THEREOF
|
CA3137397A1
(en)
|
2019-04-19 |
2020-10-22 |
Chugai Seiyaku Kabushiki Kaisha |
Chimeric receptor that recognizes engineered site in antibody
|
UY38733A
(es)
|
2019-05-30 |
2020-11-30 |
Amgen Inc |
Construcciones de arni para inhibir la expresión de scap y métodos de uso de las mismas
|
AU2020288499A1
(en)
|
2019-06-05 |
2022-01-27 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody cleavage site-binding molecule
|
US10501404B1
(en)
|
2019-07-30 |
2019-12-10 |
Factor Bioscience Inc. |
Cationic lipids and transfection methods
|
JP2022544238A
(ja)
|
2019-08-13 |
2022-10-17 |
アムジエン・インコーポレーテツド |
SLC30A8発現を阻害するためのRNAiコンストラクト及びその使用方法
|
JP2023504744A
(ja)
|
2019-12-09 |
2023-02-06 |
アムジエン・インコーポレーテツド |
LPA発現を阻害するためのRNAiコンストラクト及び方法
|
WO2021234607A1
(en)
|
2020-05-20 |
2021-11-25 |
St. Jude Children's Research Hospital |
Detection of alzheimer's disease using specific biomarkers
|
BR112022024501A2
(pt)
|
2020-06-01 |
2023-05-09 |
Amgen Inc |
Construtos de rnai para inibir a expressão de hsd17b13 e métodos de uso dos mesmos
|
EP3929295A1
(en)
|
2020-06-26 |
2021-12-29 |
Universitat Pompeu Fabra |
Artificial rnas for modulating rna fragments
|
BR112023000537A2
(pt)
|
2020-07-31 |
2023-01-31 |
Chugai Pharmaceutical Co Ltd |
Composições farmacêuticas incluindo célula que expressa o receptor quimérico
|
CA3190868A1
(en)
|
2020-08-13 |
2022-02-17 |
Amgen Inc. |
Rnai constructs and methods for inhibiting marc1 expression
|
IL302330A
(en)
|
2020-11-05 |
2023-06-01 |
Amgen Inc |
Methods for the treatment of atherosclerotic cardiovascular disease using LPA-targeted RNAi constructs
|
JPWO2022196719A1
(pt)
|
2021-03-17 |
2022-09-22 |
|
|
WO2022214887A1
(en)
|
2021-04-08 |
2022-10-13 |
Phosphogam, Llc |
Methods and compositions for enhancing the cytotoxicity of gamma/delta-t cells
|
WO2023278295A1
(en)
|
2021-06-29 |
2023-01-05 |
The Broad Institute, Inc. |
Compositions and methods for ameliorating anterodorsal thalamus hyperexcitability
|
WO2023004332A2
(en)
|
2021-07-19 |
2023-01-26 |
New York University |
Adeno-associated viral vector compositions and methods of promoting muscle regeneration
|
AU2022359289A1
(en)
|
2021-10-05 |
2024-04-04 |
Amgen Inc. |
Compositions and methods for enhancing gene silencing activity of oligonucleotide compounds
|
CN118525091A
(zh)
|
2021-10-22 |
2024-08-20 |
安进公司 |
用于抑制gpam表达的rnai构建体及其使用方法
|
EP4269586A1
(en)
|
2022-04-29 |
2023-11-01 |
Johann-Wolfgang-Goethe-Universität Frankfurt am Main |
Targeting micro rna for treatment of heart failure with preserved ejection fraction (hfpef)
|
US20240084301A1
(en)
|
2022-07-25 |
2024-03-14 |
Amgen Inc. |
Rnai constructs and methods for inhibiting fam13a expression
|
EP4353823A1
(en)
|
2022-10-12 |
2024-04-17 |
Resalis Therapeutics S.r.l. |
Inhibitors of micro-rna 22
|
WO2024130142A2
(en)
|
2022-12-16 |
2024-06-20 |
Amgen Inc. |
Rnai constructs for inhibiting ttr expression and methods of use thereof
|